Release Date: 2023-09-14

Diabetes Management with Current Guidelines.

Yusuf Karadeniz (Author)

Release Date: 2023-09-14

Diabetes mellitus (DM) and non-alcoholic fatty liver disease (NAFLD) often coexist and share underlying pathophysiological mechanisms. NAFLD encompasses a spectrum of liver conditions ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Individuals with diabetes, especially type 2 diabetes mellitus (T2DM), are at increased risk of [...]

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inCurrent Perspective on Diabetes Mellitus in Clinical Sciences
First Page133
Last Page148
DOIhttps://doi.org/10.69860/nobel.9786053359111.12
ISBN978-605-335-911-1 (PDF)
LanguageENG
Page Count16
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

Diabetes mellitus (DM) and non-alcoholic fatty liver disease (NAFLD) often coexist and share underlying pathophysiological mechanisms. NAFLD encompasses a spectrum of liver conditions ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Individuals with diabetes, especially type 2 diabetes mellitus (T2DM), are at increased risk of developing NAFLD due to insulin resistance and the associated metabolic abnormalities such as dyslipidemia and obesity. Insulin resistance promotes hepatic lipid accumulation and contributes to the pathogenesis of NAFLD by enhancing hepatic lipogenesis and suppressing fatty acid oxidation. Conversely, NAFLD exacerbates insulin resistance, creating a vicious cycle that further worsens glycemic control in diabetic patients. The presence of both conditions significantly increases the risk of cardiovascular disease and other diabetes-related complications. Management strategies include lifestyle modifications such as weight loss and physical activity, along with pharmacological interventions targeting insulin resistance and liver inflammation. Early detection and comprehensive management of both diabetes mellitus and NAFLD are crucial to mitigate their combined impact on overall health outcomes.

Yusuf Karadeniz (Author)
MD, Karaman Training and Research Hospital
https://orcid.org/0000-0002-6113-3259

  • Yu , J., Lee, S. H., & Kim, M. K. Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus. Endocrinology and metabolism (Seoul, Korea), 2022, 37(1), 26–37.

  • ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., … Gabbay, R. A., … on behalf of the American Diabetes Association 2. Classifi cation and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes care, 2023, 46(Suppl 1), S19–S40.

  • Jones, A. G., McDonald, T. J., Shields, B. M., Hagopian, W., & Hattersley, A. T. Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes. Diabetes care, 2021, 44(6), 1243–1251.

  • Owen K. R. Monogenic diabetes: old and new approaches to diagnosis. Clinical medicine (London, England), 2013, 13(3), 278–281.

  • Kahn S. E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia, 2003, 46(1), 3–19.

  • American Diabetes Association Professional Practice Committee. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. Diabetes care, 2022, 45(Suppl 1), S83–S96.

  • Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. … Buse, J. B. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care, 2022, 45(11), 2753–2786.

  • Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population. Diabetes care, 2016, 39(8), 1378–1383.

  • Peters, A.L., Laffel, L. (Eds.). American Diabetes Association/JDRF Type 1 Diabetes Sourcebook. Alexandria, VA, American Diabetes Association, 2013

  • Subramanian, S., & Baidal, D. The Management of Type 1 Diabetes. In K. R. Feingold (Eds.) et. al., Endotext. MDText.com, Inc., 2021.

  • Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., … Peters, A. L. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care, 2021,44(11), 2589–2625.

  • Tricco, A. C., Ashoor, H. M., Antony, J., Beyene, J., Veroniki, A. A., Isaranuwatchai, W., … Straus, S. E. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ (Clinical research ed.), 2014, 349, g5459.

  • Lane, W., Bailey, T. S., Gerety, G., Gumprecht, J., Philis-Tsimikas. A., Hansen, C. T., … Warren, M., Group Information, & SWITCH 1 Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA, 2017, 318(1), 33–44.

  • Home, P. D., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Rojeski, M., Espinasse, M., & Riddle, M. C. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes care, 2015, 38(12), 2217–2225.

  • Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E. The Evolution of Insulin and How it Informs Therapy and Treatment Choices. Endocrine reviews, 2020, 41(5), 733–755.

  • Malik, F. S., & Taplin, C. E. Insulin therapy in children and adolescents with type 1 diabetes. Paediatric drugs, 2014, 16(2), 141–150.

  • Vijan, S., Sussman, J. B., Yudkin, J. S., & Hayward, R. A. Effect of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA internal medicine, 2014, 174(8), 1227–1234.

  • ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., … Gabbay, R. A., … on behalf of the American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes care, 2023, 46(Suppl 1), S140–S157.

  • Matthews, D. R., Paldánius, P. M., Proot, P., Chiang, Y., Stumvoll, M., Del Prato, S., & VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet (London, England), 2019, 394(10208), 1519–1529.

  • Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., … Bolen, S. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Annals of internal medicine, 2011, 154(9), 602–613.

  • Maloney, A., Rosenstock, J., & Fonseca, V. A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clinical pharmacology and therapeutics, 2019, 105(5), 1213–1223.

  • Yalçın, M. M., & Yetkin, İ., DİABETES MELLİTUS VE KOMPLİKASYONLARININ TANI, TEDAVİ VE İZLEM KILAVUZU-2022. DİABETES MELLİTUS VE KOMPLİKASYONLARININ TANI, TEDAVİ VE İZLEM KILAVUZU, 2022 (pp.117), Ankara: Bilimsel Araştırma Yayınları.

  • Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., … Meier, J. J., & PIONEER 4 investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet (London, England), 2019, 394(10192), 39–50.

  • Singh, S., Wright, E. E., Jr, Kwan, A. Y., Thompson, J. C., Syed, I. A., Korol, E. E., … Juneja, R. Glucagon- like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes, obesity & metabolism, 2017, 19(2), 228–238.

  • Uidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Washington, DC: Department of Health and Human Services, December, 2008.

  • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (London, England), 1998, 352(9131), 854–865.

  • Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., … Raz, I., & SAVORTIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine, 2013, 369(14), 1317–1326.

  • Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., … Buse, J. B., LEADER Steering Committee, & LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 2016, 375(4), 311–322.

  • Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., … Vilsbøll, T., & SUSTAIN- 6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine, 2016, 375(19), 1834–1844.

  • Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., … REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet (London, England), 2019, 394(10193), 121–130.

  • Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., … Hernandez, A. F., & EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 2017, 377(13), 1228–1239.

  • Hernandez, A. F., Green, J. B., Janmohamed, S., D’Agostino, R. B., Sr, Granger, C. B., Jones, N. P., … Del Prato, S., & Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet (London, England), 2018, 392(10157), 1519–1529.

  • Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., … Inzucchi, S. E., & EMPAREG OUTCOME Investigators. Empaglifl ozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England journal of medicine, 2015, 373(22), 2117–2128.

  • Neal, B., Perkovic, V., & Matthews, D. R. Canaglifl ozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England journal of medicine, 2017, 377(21), 2099

  • Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., … Sabatine, M. S. The design and rationale for the Dapaglifl ozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. American heart journal, 2018, 200, 83–89.

  • Bril, F., & Cusi, K. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Diabetes care, 2017, 40(3), 419–430.

  • Dickey, R. A., & Feld, S. A new paradigm for control of diabetes. Endocrine practice : offi cial journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2002, 8(1), 65–67.

  • Monami, M., Nardini, C., & Mannucci, E. Effi cacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes, obesity & metabolism, 2014, 16(5), 457–466.

  • Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B., American Diabetes Association, & European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care, 2009, 32(1), 193–203.

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!